Market Intelligence, Clinical Progress, and High-Purity Reagents for Glioblastoma and CNS Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPRZ1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRZ1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed to preserve native glycosylation. |
View PTPRZ1 Products |
| Gene Delivery | PTPRZ1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View PTPRZ1 Products |
| Benchmark Ab | Anti-PTPRZ1 Recombinant Antibody Recombinant positive control derived from clinical/preclinical benchmark sequences. |
View PTPRZ1 Products |
| Validator | PTPRZ1 siRNA Set For target knockdown verification and specificity controls. |
View PTPRZ1 Products |
| Related Target A | EGFR Co-amplified and synergistically activated with PTPRZ1 in glioblastoma multiforme (GBM). |
View EGFR Products |
| Related Target B | CD44 Interacts within the hyaluronic acid microenvironment to drive glioma cell migration and stemness. |
View CD44 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Chondroitin Sulfate Masking | HEK293 expressed PTPRZ1 ECD-Fc preserves post-translation modifications for physiological epitope presentation. |
| Target Specificity in CNS | Sequence-verified human, mouse, and cynomolgus orthologs to rule out cross-reactivity with other receptor-type tyrosine phosphatases. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PTPRZ1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTPRZ1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T therapies specifically targeting glioblastoma multiforme (GBM). As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific glyco-epitopes and blood-brain barrier (BBB) penetrating formats.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Academic & Biotech Consortia | Glioblastoma, Astrocytoma | Internalization Assay (Need high-purity ECD-Fc to validate antibody-mediated endocytosis) |
| CAR-T / CAR-NK | Clinical-stage Biotechs | Refractory Glioma, SCLC | Cell-based binding and activation assays (Need Lentivirus for stable target-expressing cell lines) |
| Small Molecule | Academic Research Labs | Neurodegenerative diseases, Cancer | Phosphatase Activity Assays (Need recombinant intracellular active domain proteins) |